Biotech stocks rebounded with the broader market in the week ending March 18 as risk appetite returned. Multiple conference presentations, clinical readings and earnings news dictated sentiment over the week.
Synthetic Biologics, Inc.. SYN was among the biggest advances as the stock reacted to its quarterly results. On the other hand, Therapeutic Nektar NKTR came under pressure following negative results from a late study of its experimental cancer drug in combination with Bristol-Myers Squibb Company BMY Opdivivo.
Bristol-Myers Squib, meanwhile, has received Food and Drug Administration approval for its Lag-3 antibody relatilimab, in combination with Opdivo, for the treatment of advanced melanoma.
Here are the top catalysts that could move the needle on biopharma stocks over the coming week:
AD/PD 2022: International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders: March 15-22, Barcelona, Spain
KeyBanc Virtual Healthcare Conference: March 22-23
American College of Molecular Genetics and Genomics, or ACMG, Clinical Genetics Meeting: March 22-26, Nashville, Tennessee
American Academy of Dermatology, or AAD, Annual Meeting: March 25-29, in Boston, Massachusetts
from Zogenix, Inc. ZGNX the supplemental new drug application seeking approval of Fintepla as a treatment for seizures associated with Lennox-Gastaut syndrome, has a PDUFA target date of Friday, March 25.
CGPA Meeting Presentations
Applied Therapeutics, Inc. APLT: additional Phase 1/2 data for AT-007 in galactosemia (Wednesday)
Presentations from the AAD meeting
Brickell Biotech, Inc. B.B.I.: results of the pivotal phase 3 American studies Cardigan I and Cardigan II on sofpironium bromide gel, 15% in primary axillary hyperhidrosis
InflaRx SA IFRX: final data from the open-label Phase 2a study with vilobelimab in patients with pyoderma gangrenosum (Saturday)
ASLAN Pharmaceuticals Limited ASLN: Data from the Phase 1b study for eblasakimab (ASLAN004) in atopic dermatitis
Cara Therapeutics, Inc. CARA: Biomarker data from the KARE Phase 2 clinical trial evaluating oral Korsuva for the treatment of moderate to severe pruritus in patients with atopic dermatitis (Saturday)
Related Link: Why This Analyst Sees Around 20% Upside In This Large-Cap Biopharma
The list of prizes presented is not exhaustive. Click here to access Benzinga’s earnings schedule for the full schedule.
Marinus Pharmaceuticals, Inc. MRNS (before market opening)
STRATA Skin Sciences, Inc. SSKN (after closing)
DarioHealth Corp. DRIO (after closing)
TELA Bio, Inc. TELA (after closing)
Aptose Biosciences Inc. APTO (after closing)
Caladrius Biosciences, Inc. CLBS (after closing)
Vascular Biogenics Ltd. VBLT (before market opening)
PDS Biotechnology Company PDSB (before market opening)
Aptinyx Inc. APTX (after closing)
Navidea Biopharmaceuticals, Inc. NAVB (after closing)
Celcuity Inc. CELC (after closing)
Ra Medical Systems, Inc. RMED (after closing)
Titan Medical Inc. TMDI (before market opening)
HOOKIPA Pharma Inc. TO WIN OVER (before market opening)
Evelo Biosciences, Inc. EVLO (before market opening)
Athira Pharma, Inc. ATHA (after closing)
Co-Diagnostics, Inc. CDX (after closing)
Eledon Pharmaceuticals, Inc. ELDN (after closing)
Panbela Therapeutics, Inc. PBLA (after closing)
TFF Pharmaceuticals, Inc. TFFP (after closing)
POINT Biopharma Global Inc. NTP (before market opening)
Related Link: Attention Biotech Investors: Mark Your Calendar for March PDUFA Dates